Insiders who reported open-market trades in the last 12 months at the companies Shao-Lee Lin files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Sumita Ray - $266K in CUE purchases and sales in the last 12 months
Shao-Lee Lin is a corporate insider, tracked as Chief Executive Officer, Director of Cue Biopharma, Inc. (CUE). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Shao-Lee Lin submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Shao-Lee Lin been buying or selling stock?
Recorded transactions: 2 open-market purchases ($1000K) and 5 open-market sales ($1.61M) across all tracked filings.
Shao-Lee Lin is Chief Executive Officer, Director of Cue Biopharma, Inc. (CUE). 5 SEC Form 4 filings on record, most recently on 15 August 2026. Most recent open-market trade: sold $308K of CUE on 15 August 2026. Lifetime open-market purchases: $1000K. Lifetime open-market sales: $1.61M.
Recent transactions
8
The latest 8 SEC Form 4 transactions reported by Shao-Lee Lin.
InsiderAlpha's records for Shao-Lee Lin go back to 2026: 5 primary Form 4 filings, an average of 5.0 per year. The typical open-market purchase is $1000K (1 of 2 buys carry a usable dollar value, totaling $1000K). The largest single buy on record is $1000K of CUE in 2026. Sales side: 5 recorded sales totaling $1.61M, so the filing history runs sell-heavy by dollar value. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
